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PollutionThe burgeoning obesity epidemic has placed enormous strains on individual and societal health mandating a
careful search for pathogenic factors, including the contributions made by endocrine disrupting chemicals
(EDCs). In addition to evidence that some exogenous chemicals have the capacity to modulate classical hor-
monal signaling axes, there is mounting evidence that several EDCs can also disrupt metabolic pathways and
alter energy homeostasis. Adipose tissue appears to be a particularly important target of these metabolic dis-
ruptions. A diverse array of compounds has been shown to alter adipocyte differentiation, and several EDCs
have been shown to modulate adipocyte physiology, including adipocytic insulin action and adipokine secre-
tion. This rapidly emerging evidence demonstrating that environmental contaminants alter adipocyte func-
tion emphasizes the potential role that disruption of adipose physiology by EDCs may play in the global
epidemic of metabolic disease. Further work is required to better characterize the molecular targets respon-
sible for mediating the effects of EDCs on adipose tissue. Improved understanding of the precise signaling
pathways altered by exposure to environmental contaminants will enhance our understanding of which
chemicals pose a threat to metabolic health and how those compounds synergize with lifestyle factors to pro-
mote obesity and its associated complications. This knowledge may also improve our capacity to predict
which synthetic compounds may alter energy homeostasis before they are released into the environment
while also providing critical evidentiary support for efforts to restrict the production and use of chemicals
that pose the greatest threat to human metabolic health. This article is part of a Special Issue entitled: Mod-
ulation of Adipose Tissue in Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. The obesity epidemic and endocrine disruption
The last several decades have witnessed a dramatic deterioration
in global metabolic health with the emergence of the obesity and
diabetes epidemics. In the United States over two-thirds of the adult
population is overweight, with more than a third characterized as
obese [1]. Importantly, children are among the groups with the fastest
rising rates of obesity [2,3]. The societal burden of obesity and its
metabolic complications is signiﬁcant, with annual obesity-related
healthcare costs in the United States estimated at $147 to $210 billion
[4]. It is expected that these costs will rise dramatically as the global
burden of obesity-related illnesses such as diabetes increase from
approximately 371 million individuals worldwide in 2012 to a stagger-
ing 552 million people by 2030 [5,6]. With healthcare costs rising
unsustainably [7], addressing the myriad factors contributing to the
burgeoning metabolic disease epidemic is critical for improvingion of Adipose Tissue in Health
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is).
l rights reserved.individual health aswell as the ﬁnancial viability of health care systems
around the world.
Increased consumption of highly palatable and calorically dense
foods coupled with increased physical inactivity are undoubtedly
central drivers of the metabolic disease epidemic; however, these fac-
tors alone fail to fully account for the rapidity and magnitude of the
rise in obesity and diabetes rates. Likewise, shifts in population genet-
ics are unlikely to occur on a time scale that explains the recent dete-
rioration in humanmetabolic health. As such, increasing attention has
turned to the identiﬁcation of additional factors that may impact
energy metabolism, including exposure to chemical pollutants [8].
First articulated in 1992, the theory of endocrine disruption postu-
lates that exogenous chemicals can modulate homeostasis by inter-
fering with the action of endogenous hormonal axes [9]. Since the
theory's inception, a host of endocrine disrupting chemicals (EDCs)
have been identiﬁed, including industrial products and waste, ﬂame
retardants, phytochemicals, pharmaceuticals, pesticides, food addi-
tives, and personal care products (Fig. 1). Humans are exposed to
these compounds via multiple routes, including ingestion, inhalation,
injection, transdermal contact, and transplacental carriage [10]. Initial
studies of EDCs focused on their capacity to disrupt sex steroid signaling
[11–13] through modulation of estrogenic [14,15] and/or androgenic
Pesticides, Herbicides, and Fungicides
Phytochemicals and
Food Colorings
Personal Care Products
and Household Supplies
Pharmaceuticals and
Medical Devices
Industrial Products
and Waste
Furniture
Clothing
Plastic Children’s Toys and 
Plastic Bottles
Fig. 1. Adipocytes Under Assault: endocrine disrupting chemicals and their sources. BPA, bisphenol A; DDT, dichlorodiphenyltrichloroethane; DEHP, di-2-ethylhexyl phthalate; DES,
diethylstilbestrol; MEHP, mono-ethylhexyl phthalate; 4-NP, 4-nonylphenol; PBDEs, polybrominated diphenyl ethers; PCB, polychlorinated biphenyl; TF, tolylﬂuanid; TBT, tributyltin;
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TFZ, triﬂumizole.
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roid hormone signaling were identiﬁed [18–20]. More recently, atten-
tion has turned to the capacity of environmental contaminants to
disrupt metabolic pathways.
The concept that EDCs might alter energy metabolism and con-
tribute to the development of metabolic diseases was ﬁrst proposed
in 2002 by Paula Baillie-Hamilton who noted the coordinate increases
in the rates of overweight/obesity and synthetic chemical production
in the United States [21]. This ultimately led to the articulation of the
“environmental obesogen hypothesis” by Grun and Blumberg in
2006, which postulated a causal link between “obesogens” in the
environment and the obesity epidemic [22]. In support of this theory
is an expanding body of epidemiological studies correlating various
chemicals with elevated body weight in humans [reviewed in Refs.
[23–25]], as well as literature linking exposure to synthetic chemicals
with diabetes [reviewed in Ref. [26]]. Interestingly, increases in body
weight have also been documented in domesticated, feral, and labo-
ratory animals in industrialized countries [27]. These ﬁndings suggest
that obesogenic agents in the environment may play an important
role in promoting the accretion of fat mass beyond that induced by
lifestyle factors alone.
While links between environmental contaminants and the epi-
demic of metabolic disease have generated signiﬁcant interest and in-
clusion in national obesity research recommendations [28–30], many
questions remain regarding the molecular mechanisms by which
these compounds contribute to the pathogenesis of metabolic dis-
eases. For several reasons, adipose tissue is likely a critical target for
metabolic disruption by EDCs. First, adipose tissue is a dynamic
organ centrally involved in the integrative network that maintains
global energy homeostasis. Second, many classes of EDCs are highlylipophilic and predicted to bioaccumulate in the lipid droplet of
mature adipocytes resulting in high local concentrations in the fat
pad [31]. Third, bioaccumulation of EDCs in adipose tissue may result
in sustained local exposure of adipocytes after acute enrichment
through slow leaching from the lipid droplet. Fourth, adipocyte phys-
iology is tightly regulated by multiple nuclear hormone receptors that
have lipophilic compounds as their endogenous ligands, and several
of these receptors have emerged as molecular targets of various
EDCs [32,33]. Consequently, adipocytes are primed for metabolic
disruption by EDCs. Furthermore, adipose tissue likely serves as a
reservoir of bioactive EDCs that can be released into the systemic
circulation or sequestered in the adipocyte lipid droplet in response
to hormonal and neuronal signals regulating adipose physiology.
Thus, alterations in adipose tissue function can modulate EDC ﬂux
from this storage depot, thereby inﬂuencing the function of other
metabolic tissues. Understanding how these environmental pollut-
ants modulate adipose development and function is critical for deter-
mining their potential role in the pathogenesis of metabolic diseases.
2. EDCs promote adiposity and weight gain in animal models
Supporting the emerging epidemiological evidence linking chemi-
cal exposures with obesity and its metabolic consequences in humans
[reviewed in refs. [23–26]], animal studies have identiﬁed a variety
of compounds with the capacity to alter adipose mass and energy
homeostasis. Tributyltin (TBT) is a persistent organic pollutant (POP)
that has been used as a fungicide and, until recently banned, as an
antifouling agent in marine paints. Male C57BL/6 mice acutely ex-
posed to TBT exhibited augmented gene expression of the adipogenic
markers CCAAT enhancer binding protein-β (C/EBPβ) and sterol
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Fig. 2. Regulation of adipocytic differentiation. AMPK, 5′-adenosine monophosphate-
activated protein kinase; AP-2, adipocyte protein-2; BMP4, bone morphogenetic protein-4;
CDK, cyclin-dependent kinase; C/EBP, CCAAT-enhancer-binding protein; CHOP10, C/EBP ho-
mologous protein-10; CREB, cAMP response element-binding protein; FBS, fetal bovine
serum; GH, growth hormone; GR, glucocorticoid receptor; GSK-3β, glycogen synthase
kinase-3β; Hh, hedgehog; IGF-1, insulin-like growth factor-1; Insig-2a, insulin induced
gene-2a; IR, insulin receptor; JAK, Janus kinase; MAPK, mitogen-activated protein kinase;
mTORC1, mammalian target of rapamycin complex-1; PKA, protein kinase A; PPAR, peroxi-
some proliferator-activated receptor; Pref-1, preadipocyte factor-1; PRL, prolactin; Rb, reti-
noblastoma; RXR, retinoid X receptor; Sp1, speciﬁcity protein-1; SREBP1c, sterol
regulatory element-binding transcription factor-1c; STAT, signal transducer and activator
of transcription.
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sure resulting in increased adipose mass in 10-week old males [34].
Interestingly, the obesogenic effect of TBT was species-independent
as developmental exposure of Xenopus laevis resulted in an increase
in ectopic adipocyte formation as well [34]. The obesity-promoting
action of TBT has been conﬁrmed in male KM mice [35], making TBT
the prototypical environmental obesogen. The ability of TBT to pro-
mote the accretion of adiposity has been linked to its ability to func-
tion as a nanomolar agonist of peroxisome proliferator-activated
receptors (PPARs) and retinoid X receptor α (RXRα) [36].
Polychlorinated biphenyls (PCBs) are a family of congeners that
found wide industrial use as dielectric and coolant ﬂuids. Despite
being banned in the United States in 1979, the extensive use and
chemical stability of these compounds have resulted in their persis-
tence in the environment. Adult male C57BL/6 mice exposed to
PCB-77 showed increased body weight gain, an effect that was depen-
dent on the aryl hydrocarbon receptor (AhR), as AhR-null mice did
not exhibit the same PCB-induced increase in body weight [37]. In a
recent series of papers, it was shown that one-time exposure of
adult male C57BL/6J mice to the compounds diethylstilbestrol (DES)
[38], 4-nonylphenol (4-NP) [39], and mono-2-ethylhexyl phthalate
(MEHP) [40] resulted in increased adipose gene expression of PPARγ,
adipocyte protein 2 (aP2), and lipoprotein lipase (LPL), markers of adi-
pocyte development. Interestingly, developmental exposure to MEHP
increased body weight and adiposity in males, while similar exposure
to DES or 4-NP augmented weight gain and adiposity only in females.
In contrast, exposure to MEHP's parent compound di(2-ethylhexyl)
phthalate (DEHP) in adult female C3H/N mice resulted in augmented
food consumption, body weight gain, and visceral adiposity, a pheno-
type that was also observed in the offspring of exposed females [41].
Because DEHP is metabolized to MEHP in vivo, the obesogenic effect of
DEHP in these studies may result, wholly or partly, from MEHP expo-
sure. Extending the existence of obesogens into other model organisms,
exposure of zebraﬁsh to an environmentally relevant mixture of POPs
consisting of multiple ﬂame retardant polybrominated diphenyl ethers
(PBDEs), the organochlorine insecticide dichlorodiphenyltrichloroethane
(DDT), and PCBs resulted in signiﬁcantly increased mean body weight
[42]. Other EDCs have also been implicated in the promotion of weight
gain and adiposity in animalmodels at some levels of exposure, including
lead [43], bisphenol A (BPA) [44,45], PCB-126 [46], organophosphate
insecticides [47,48], the widely used herbicide atrazine [49], and the
fungicide triﬂumizole [50].
In contrast to these studies, several compounds have also been
shown to decrease body weight and adiposity. For example, adult
male C57BL/6 mice exposed to perﬂuorooctanoic acid (PFOA), a POP
used industrially as a surfactant, exhibited reduced adipose mass
[51], while the fungicide triphenyltin (fentin, TPT) attenuated weight
gain in golden hamsters [52]. Likewise, other models examining the
metabolic effects of DEHP have shown protection from diet-induced
obesity in C57BL/6J mice [53], weight loss in male Crlj:CD1 mice
[54], and reduced weight gain and adipose mass in male Wistar rats
[55,56]. Collectively, these studies suggest that a structurally and
functionally diverse array of environmental contaminants have the
capacity to modulate body weight and fat mass; however, much less
is known about the mechanisms by which these compounds act to
promote alterations in adipose mass or function.
3. Exogenous modulation of adipocyte development
Under conditions of caloric excess, adipose mass is expanded via
both adipocyte hypertrophy and hyperplasia, with new adipocytes
recruited from adipose stromal mesenchymal stem cells (MSCs) to the
adipocyte lineage (preadipocytes) and subsequently differentiated
into mature adipocytes [57,58]. The development of adipocytes from
MSCs is tightly regulated through the coordinated action of multiple
signaling pathways [reviewed in ref. [59]] (Fig. 2). Because expansionof the adipocyte pool is critical for safely storing excess lipid, under-
standing how these signaling axes can be altered by EDCs is critical for
appreciating how environmental contaminants might contribute to
the development of metabolic diseases.
MSCs have the capacity to differentiate into myocytes, osteoblasts,
chondrocytes, and preadipocytes. Recently, studies have begun inves-
tigating the capacity of EDCs to promote MSC differentiation into the
adipocyte lineage (Table 1). For example, TBT was shown to induce
adipogenesis from human and mouse adipose-derived MSCs [60].
Using the murine C3H/10T1/2 MSC cell line, DEHP and TBT were also
shown to enhance adipogenesis while BPA impaired adipocyte differ-
entiation [61]. Current evidence suggests that MSC-to-preadipocyte
development is stimulated by bone morphogenic proteins (BMPs)
operating through Smad transcription factors, with a potential role
for Wnt signaling in promoting preadipocyte commitment; in con-
trast, hedgehog (Hh) signaling and potentially retinoblastoma (Rb)
inhibit MSC-to-preadipocyte differentiation [59]. Whether these or
other EDCs promote MSC differentiation to the adipocyte lineage
through an augmentation of BMP/Smad or Wnt signaling or through
an inhibition of Hh or Rb pathways remains unknown.
Model systems such as the 3T3-L1 preadipocyte cell line [62] have
greatly advanced our understanding of the signaling events regulating
Table 1
EDC effects on adipocyte development. Upward-facing arrows indicate that the study demonstrated an augmentation of adipogenesis in the speciﬁed period of adipocyte develop-
ment; a downward-facing arrow indicates attenuation of adipocyte differentiation. BADGE, bisphenol A diglycidyl ether; DEHP, di-2-ethylhexyl phthalate; DES, diethylstilbestrol;
hADSC, human adipose derived stem cells; hBMC, human bone marrow cells; hMSC, human mesenchymal stem cells; mADSC, murine adipose derived stem cells; MBuP, monobutyl
phthalate; MBzP, monobenzyl phthalate; mdMSC, murine marrow derived mesenchymal stem cells; MEHP, mono-ethylhexyl phthalate; mMSC, murine mesenchymal stem cells;
PCB, polychlorinated biphenyl; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
EDC and model system Dose MSC → preadipocyte Preadipocyte → adipocyte
PCB-77
3T3-L1 [37] 3.4 μM ↑ (Reduced at higher dose)
TCDD
3T3-L1 [101] .1–30 nM ↓
MEHP (phthalate)
3T3-L1 [68] 10–100 μM ↑ (Dose responsive)
3T3-L1 [40] 1–100 μM ↑ (Dose responsive)
3T3-L1 [165] 50 μM ↑
DCHP (phthalate)
3T3-L1 [32] 100 nM ↑
MBzP (phthalate)
3T3-L1 [165] 100–300 μM ↑ (Dose responsive)
MBuP (phthalate)
3T3-L1 [165] 100–300 μM ↑ (Dose responsive)
DEHP (phthalate)
C3H/10 T1/2 [61] 100 μM ↑ (Not seen at 100 nM)
Nonylphenol
3T3-L1 [39] 100 nM–10 μM ↑ (Dose responsive, not seen at lower doses)
Tributyltin
3T3-L1 [34] 10–100 μM ↑ (Dose responsive)
3T3-L1 [166] 50–100 nM ↑
mADSC, hADSC [60] 50 nM ↑ (Not seen at 5 nM)
C3H/10 T1/2 [61] 100 nM ↑ (Not seen at 1 nM)
hBMC [167] 1–10 nM ↑
Tolylﬂuanid
3T3-L1 [32] 100 nM ↑
Triﬂumizole
3T3-L1 [50] 10 nm–10 μM ↑ (Dose responsive)
hADSC [50] 100 nM ↑
Endrin
3T3-L1 [32] 100 nM ↑
Bisphenol A
3T3-L1 [32] 100 nM ↑
3T3-L1 [168] 20–80 μM ↑ (Dose responsive)
3T3-L1 [169] 10–100 nM ↑
mMSC, hMSC [169] 1–1000 nM No signiﬁcant effect
C3H/10 T1/2 [61] 10 μM ↑ (Not seen at 10 nM)
HgCl2
3T3-L1 [170] 5–10 μM ↓ (Dose responsive, not seen at lower doses)
C3H/10 T1/2 [170] 5–10 μM ↓ (Dose responsive, not seen at lower doses)
BADGE
3T3-L1 [169] 10 nM ↑
mMSC [169] 10–100 nM ↑ (Dose responsive, no effect at higher/lower dose)
hMSC [169] 10–1000 nM ↑ (Dose responsive, no effect at lower dose)
DES
3T3-L1 [38] 1–10 μM ↑ (Dose responsive)
Phenamil (Amiloride derivative)
3T3-L1, 3T3-F442A [171] 10 μM ↑
Flavanone
3T3-L1 [70] 10–100 μM ↑ (Dose responsive, maximal at 30 μM)
Indomethacin
C3H/10 T1/2, mdMSCs [172] 10–50 μM ↑ (Dose responsive)
Bixin (natural food coloring)
3T3-L1 [71] 30–70 μM ↑ (Dose responsive)
Emodin (rhubarb derivative)
3T3-L1 [173] 25–50 μM ↑ (Dose responsive, no effect at higher/lower dose)
Sildenaﬁl
3T3-L1 [174] 10–40 μM ↑ (Dose responsive)
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pocytes can be induced to differentiate into mature adipocytes with
an induction cocktail that includes glucocorticoids, insulin, an agent to
raise intracellular cAMP, and fetal bovine serum (FBS) [63]. This
stimulation results in the development of mature adipocytes through
a carefully choreographed cascade of transcription factor activation,
including the glucocorticoid receptor (GR), PPARγ, RXRα, cAMP re-
sponse element-binding protein (CREB), C/EBPs, and SREBP1c (Fig. 2)
[64]. More recent evidence suggests a critical role for the JAK–STAT
pathway in promoting adipogenesis [reviewed in ref. [65]]. Negativeregulation of preadipocyte-to-adipocyte differentiation is thought to
occur principally through Pref-1 activation of Sox9 signaling [66].
A host of chemicals have been shown to induce preadipocyte-
to-adipocyte differentiation (Table 1). Interestingly, EDCs shown to
promote adipogenesis are structurally diverse, suggesting that they
may promote adipocyte differentiation through distinct pathways.
PPARγ, the widely regarded “master regulator” of adipogenesis [67], is a
ligand-activated nuclear hormone receptor with a large ligand-binding
domain that accommodates structurally diverse ligands, making it a
prime target for endocrine disruption [33]. The prototypical obesogen
524 S.M. Regnier, R.M. Sargis / Biochimica et Biophysica Acta 1842 (2014) 520–533TBTwas identiﬁed as a high afﬁnity, nanomolar agonist for PPARα, PPARδ,
and PPARγ as well as their shared heteromeric partner RXRα [34,36];
obesogenic phthalates such asDEHP andMEHPare also known to activate
PPARγ [41,68]. Several other EDCs including some ﬂame retardants [69],
triﬂumizole [50], the phytochemical ﬂavanone [70], and bixin, a natural
compound commonly used in food coloring [71], have also been shown
to function as PPARγ agonists, raising the possibility that they may alter
adipose development and function through modulation of this critical
transcription factor.
It is important to note that PPARγ activation results in heteroge-
neous patterns of gene/protein expression that are ligand-dependent
[72]. This has been observed with pharmacological ligands as well as
with EDCs. For example, compared to the pharmacological PPARγ
agonist rosiglitazone, exposure of adipocytes to the phthalate MEHP
induces expression of only a subset of PPARγ-dependent genes, primar-
ily those related to adipogenic differentiation [68]. Because the func-
tional state of the adipocyte is critical for regulating global energy
metabolism, it is vital that studies examining putative obesogens func-
tioning as PPARγ ligands broadly assess the metabolic phenotype of
those adipocytes, particularly since pharmacological PPARγ agonists
improve insulin sensitivity. Thus, EDCs with PPARγ activity may have
salutary effects on metabolism depending on the ultimate phenotype
of the adipocyte, which will be at least partially dictated by the pattern
of adipocyte gene expression induced by the speciﬁc compound.
Another ligand-activated nuclear hormone receptor that plays a
critical role in adipogenesis is the GR. Using a low potency differenti-
ation cocktail, BPA, dicyclohexyl phthalate (DCHP), endrin, and
tolylﬂuanid (TF) were shown to promote 3T3-L1 differentiation, like-
ly through GR activation [32]. This mechanism of BPA-induced
adipogenesis is supported by in silico modeling suggesting that BPA
can bind the GR as an agonist [73]. TF-mediated alterations in GR sig-
naling was suggested by data showing that this fungicide had the
capacity to displace radiolabeled glucocorticoid from the GR [74],
and more recent evidence has shown that TF can stimulate GR signal-
ing in primary murine adipocytes [75]. In addition to direct stimula-
tion of the receptor, glucocorticoid signaling is also regulated by the
interconversion of glucocorticoids between active and inactive states
through the enzymatic action of 11β-hydroxysteroid dehydrogenase
type 1 and 2 (11β-HSD-1/2). The 11β-HSD-2 enzyme primarily
inactivates glucocorticoids in the kidney to help regulate blood pres-
sure, and several EDCs have been shown to inhibit this enzyme,
including organotins [76], dithiocarbamates [77], phthalates [78],
perﬂuoroalkylated compounds [79], silanes [80], and some antibiotics
[80]. While EDC-mediated inhibition of 11β-HSD-2 may contribute to
the development of hypertension, the effect of these compounds in
adipose tissue is less clear given the low levels of this enzyme found
in fat. In contrast, 11β-HSD-1 is a bidirectional enzyme that is receiv-
ing increasing attention as a contributor to metabolic disease and,
therefore, as a potential therapeutic target [81]. Whether EDCs
modulate the activity or directionality of 11β-HSD-1 is an important
question necessitating further study.
Increased fat mass has clear deleterious effects on metabolism;
however, failure to increase adipose tissue mass in the face of caloric
excess also adversely impacts metabolic homeostasis, as is seen
clinically in lipodystrophic states [82,83]. While a central focus of
EDC research has been on identifying pro-adipogenic compounds,
chemicals that antagonize endogenous signals promoting adipocyte
differentiation may also be harmful, particularly when coupled with
the metabolic stress of caloric excess. To date, several EDCs have
been shown to impair adipogenesis (Table 1), with some compounds
exerting differential effects depending on the experimental context.
Further studies are required to characterize the metabolic conse-
quences of anti-adipogenic EDCs, especially in the context of caloric
excess in which these two metabolic stressors may synergize to dis-
rupt energy homeostasis by promoting adipocyte hypertrophy and
ectopic fat deposition.While an increasing body of evidence implicates EDC-mediated
activation of PPARγ and the GR in promoting adipogenesis, less is
known about compounds that activate other signaling pathways
regulating adipocyte development. The role of sex steroids in body
fat distribution has been recognized since 1956 [84], with android
and gynoid forms of obesity associated with more visceral or subcuta-
neous fat, respectively [reviewed in ref. [85]]. Because visceral fat is
particularly deleterious to metabolic health, EDCs that modulate fat
distribution may have unique effects on metabolism that could be
mediated through disruption of sex steroid signaling, a common tar-
get of EDCs [reviewed in ref. [10]]. Likewise, modulation of estrogen
and androgen signaling, which is likely dependent on the endogenous
hormonal milieu, may explain sexually dimorphic metabolic effects
observed with some EDCs [38–40,86,87]. Furthermore, identiﬁcation
of compounds that modulate the adipogenic pathway through differ-
ent mechanisms might help predict which interactions among EDCs
are antagonistic, additive, or synergistic with respect to body weight
gain and metabolic disturbances. This is an important consideration
given the approximately 100,000 unique chemicals to which humans
are exposed [88]. Finally, emerging evidence suggests that white adi-
pose tissue has the capacity to “brown” and increase energy utiliza-
tion [89–92], a process that may improve energy metabolism;
whether and by which mechanisms EDCs affect this process remains
largely unresolved.
4. Modulation of adipocyte metabolism
Adipocytes play a central role in regulating metabolic homeosta-
sis, storing energy during periods of caloric surfeit and mobilizing
those stores during periods of caloric deﬁcit. The transition between
these states is governed by circulating hormones, principally insulin
during periods of energy excess and catecholamines when energy
mobilization is required [93,94]. EDCs that disrupt this carefully coor-
dinated regulation of adipocyte metabolism may result in distur-
bances in global energy metabolism that promote the development
of diabetes, dyslipidemia and cardiovascular disease (Table 2).
Because absolute or relative insulin deﬁciency is central to the devel-
opment of type 1 and type 2 diabetes, respectively, EDCs that modu-
late the action of this anabolic hormone in adipose tissue may be of
paramount importance in environmentally-induced metabolic dis-
eases [reviewed in ref. [95]].
POPs are found at high concentrations in the oils from fatty ﬁsh,
providing an important source of human exposure to these com-
pounds. Compared to a high fat diet containing puriﬁed ﬁsh oil, con-
sumption of crude ﬁsh oil naturally enriched in lipophilic POPs
induced insulin resistance, abdominal obesity, and hepatic steatosis
in male Sprague–Dawley rats [96]. Similar effects were observed in
adult male C57BL/6J mice fed a diet including farmed salmon high
in POPs, which also induced cellular insulin resistance [97]. Exposure
of female Wistar rats to DEHP during development resulted in insulin
resistance in adulthood [98], and exposure of adult male Wistar rats
resulted in insulin resistance in adipose tissue, potentially through a
reduction in AS160 and GLUT4 protein levels [99]. Adipocytes from
Sprague–Dawley rats exposed to PBDEs for four weeks exhibited a
reduction in insulin-stimulated glucose oxidation [100], while studies
using 3T3-L1 adipocytes have demonstrated that exposure to POPs
including organochlorine pesticides [96] and the prototypical dioxin
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [101] attenuate insulin-
stimulated glucose uptake. While these studies provide important
insight into the functional outcomes of EDC exposure, further studies
are required to identify the molecular mechanisms responsible for the
insulin resistance induced by these compounds.
Studies examining the effects of the phenylsulfamide fungicide
and antifouling agent TF identiﬁed this EDC as an insulin disruptor
in adipose tissue [102]. The impairment in insulin action was likely
a result of activation of glucocorticoid signaling [75], a pathway of
Table 2
EDCs modulate adipocyte metabolism and endocrine function. CD-36, cluster of differentiation 36; DCHP, dicyclohexyl phthalate; DEHP, di-2-ethylhexyl phthalate; DES, diethylstilbestrol; DiBP, diisobutyl phthalate; GTT, glucose tolerance
test; HFD, high fat diet; IL-6, interleukin-6; IL-8, interleukin 8; IR, insulin resistance; ITT, insulin tolerance test; MCP-1, monocyte chemoattractant protein-1; MEHP, mono-ethylhexyl phthalate; OP, organophosphate; PBDE, Polybrominated
diphenyl ether; PFOA, perﬂuorooctanoic acid; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TNFα, tumor necrosis factor-α.
EDC and model system Leptin Adiponectin Inﬂammatory mediators Resistin Lipogenesis/lipolysis Adipocyte morphology Glucose homeostasis
Bisphenol A
OF-1 pregnant mice [87] ↑ plasma conc. [87] Impaired GTT; IR
ICR mice (perinatal exposure) [117] ↑ plasma conc.
(correlated w/adipose mass)
3T3-L1 adipocytes [119] ↑ mRNA expression [32] ↑ protein levels [106] ↑ basal and insulin-
stimulated glucose uptake
Human adipose explants [121,126]↓ secretion [126] ↑ secretion (TNFα,
IL-6)
Sprague–Dawley rat (perinatal
exposure)
[45] ↑ lipolytic gene
expression
[45] Hypertrophy
OF1 male mice [138] Impaired GTT; IR
Wistar rat (perinatal exposure) [175] Impaired GTT; IR
PCB-77
3T3-L1 adipocytes [37] ↓ mRNA and
secretion
[37] ↑ mRNA (TNFα, CD-36)
ApoE−/− mice [37] Hypertrophy
Benzo[a]pyrene
C57Bl/6 male mice [108] ↓ leptin:body weight
ratio
[108] ↓ β-adrenergic
stimulated lipolysis
Tributyltin
KM male mice [35] ↑ plasma conc. [35] ↓ plasma conc. [35] ↑ plasma conc.
Trimethyltin
SW872 human adipose cell line [176] ↓mRNA at 3 h; ↑mRNA
at 48 h; ↓ secretion at 24 and
48 h
[176] ↑ mRNA and secretion
(TNFα, IL-6)
PFOA
CD-1 female mice (in utero
exposure)
[118] ↑ plasma conc. [118] ↑ plasma insulin conc.
DES
CD-1 mice (in utero exposure) [177] ↑ plasma conc. [177] ↑ plasma conc. [177] ↑ plasma conc. (IL-6) [177] ↓ plasma insulin conc.
CD57Bl/6 J female mice (perinatal
exposure)
[38] ↑ lipogenic gene
expression
[38] ↑ plasma glucose conc.
Nonylphenol
C57BL/6J female mice (perinatal
exposure)
[39] ↑ plasma glucose conc.
3T3-L1 adipocytes [125] ↑ mRNA [125] mRNA levels exhibit
inverse dose response
relationship
[125] ↑ mRNA
Octylphenol
3T3-L1 adipocytes [125] ↑ mRNA [125] ↓ mRNA [125] ↑ mRNA and
protein expression
C57BL/6J male mice [125] ↑ adipose mRNA and
plasma conc.
[125] ↓ plasma conc. [125] ↑ adipose mRNA
and plasma conc.
[125] ↑ plasma glucose conc.
TCDD
Human multipotent adipose-
derived stem cells
[124] ↑ mRNA (IL-8,
MCP-1); ↑ secretion (IL-8)
C57BL/6 male mice [124] ↑ macrophage
inﬁltration of adipose
[178] ↓ plasma insulin conc.
English shorthair male guinea pigs [179] ↓ glucose uptake in
adipose, pancreas
Nicotine
Sprague–Dawley rats
(in utero exposure)
[180] Hypertrophy [180] Impaired GTT/ITT; IR
(continued on next page)
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PBDE
Sprague–Dawley male rats [100] ↑ isoproterenol
stimulated lipolysis
[100] ↓ insulin-stimulated
glucose oxidation in adipose
Atrazine
Sprague–Dawley male rats [49] ↑ plasma glucose conc.;
impaired GTT; IR
Tolylﬂuanid
C57Bl/6 male mice [102] ↓ secretion [75] ↓ mRNA in adipose [75] ↑ insulin-stimulated
lipogenesis
[102] ↓ insulin-stimulated
Akt phosphorylation
CD-1 male mice [102] ↓ insulin-stimulated
Akt phosphorylation
Sprague–Dawley male rats [102] ↓ insulin-stimulated
Akt phosphorylation
Wistar–Kyoto male rats [102] ↓ insulin-stimulated
Akt phosphorylation
Human adipose explants [102] ↓ insulin-stimulated
Akt phosphorylation
3T3-L1 adipocytes [32] ↑ protein levels
Endrin
3T3-L1 adipocytes [32] ↑ protein levels
Chlorpyrifos (OP)
Long–Evans rats (perinatal
exposure)
[86] Altered leptin:body
weight ratio
Dimethoate (OP)
Wistar–CFT male rats [181] Impaired GTT
Diazinon (OP)
Goto–Kakizaki male rats [182] Impaired GTT
Malathion (OP)
Wistar male rats [183,184]↑ plasma glucose
conc. and insulin conc.
Parathion (OP)
Sprague–Dawley male rats
(neonatal exposure)
[185] ↑ plasma conc. [185] ↑ plasma conc. at
low dose (chow); ↓ plasma
conc. at high dose (HFD)
[185] ↑ conc. in inguinal
adipose depot
Sprague–Dawley female rats
(neonatal exposure)
[185] ↓ plasma conc. (HFD) [185] ↑ conc. in mesenteric
adipose depot
DiBP (phthalate)
Wistar fetal rats (in utero
exposure)
[186] ↓ plasma conc. [186] ↓ plasma insulin conc.
DEHP (phthalate)
C3H/N female mice [41] ↑ adipose mRNA;
↑ plasma conc.
[41] ↓ adipose mRNA [41] Hypertrophy
Wistar male rats [56] Atrophy [187] Impaired GTT; ↑ plasma
glucose conc.
Wistar male rats (in utero
exposure)
[98] 27 weeks: ↑ plasma insulin
conc.; IR on GTT
Wistar female rats (in utero
exposure)
[98] 27 weeks: ↑ plasma
glucose conc.; ↓ plasma
insulin conc.; impaired GTT
Wistar albino male rats [99] ↑ plasma glucose conc.;
↓ insulin-stimulated glucose
uptake in adipose
MEHP (phthalate)
C57Bl/6 male mice (perinatal
exposure)
[40] ↑ plasma glucose conc.
DCHP (phthalate)
3T3-L1 adipocytes [32]
↑ protein levels
Table 2 (continued)
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attenuation of insulin signal transduction resulted from a speciﬁc
down-regulation in insulin receptor substrate-1 (IRS-1) levels [102].
IRS proteins are an attractive target for EDC-mediated disruption of in-
sulin action. While activated by tyrosine phosphorylation mediated by
the insulin receptor, these proteins contain multiple serine/threonine
residues whose phosphorylation attenuates transmission of the insulin
signal [104]. Multiple signaling cascades, including those induced by
tumor necrosis factor-α (TNFα), resistin, free fatty acids, and diac-
ylglycerol promote phosphorylation of these serine/threonine sites,
suggesting that IRS proteins integrate multiple cellular signals to set
the insulin responsiveness of the cell [105]. From an endocrine disrup-
tion standpoint, this suggests that structurally unique EDCsmodulating
distinct cell signaling cascades may be able to promote the induction of
insulin resistance through convergent effects on IRS proteins.
In contrast to data demonstrating EDC-mediated insulin resis-
tance, one study has shown that BPA enhances insulin-independent
and -dependent glucose uptake in 3T3-L1 adipocytes [106]. It is not
entirely clear what signiﬁcance this holds given that the concentra-
tion used in this study was in the high micromolar range, a concentra-
tion unlikely to be relevant for human exposures. The interpretation
of these ﬁndings is further complicated by a study showing that BPA
exposure led to insulin resistance in a male mouse model [107]. How-
ever, these ﬁndings illustrate the fact that, while most focus is on the
deleterious effects of synthetic chemicals on energy metabolism, it is
possible that some compounds may exert beneﬁcial effects. Interest-
ingly, characterization of such compounds could provide serendipi-
tous evidence of pathways that might serve as novel targets for
pharmaceutical agents.
The effects of EDCs on other hormones regulating adipocyte
metabolism are less well-studied. Adipose tissue from Sprague–Dawley
rats exposed to PBDEs exhibited enhanced isoproterenol-induced
lipolysis [100], while exposure of C57BL/6J mice to the polyaromatic
hydrocarbon benzo[a]pyrene resulted in adipose tissue that was
resistant to catecholamine-induced lipolysis [108]. Because of
insulin's prominent role in modulating catecholamine action in adi-
pose tissue, these ﬁndings may reﬂect effects on adipocytic insulin
action; however, speciﬁc alterations in catecholamine signal trans-
duction should be explored in further mechanistic detail. Because
catecholamines signal through cAMP, it is interesting that dioxin-like
PCBs were shown to attenuate hepatocyte up-regulation of phos-
phoenolpyruvate carboxykinase gene expression in response to
forskolin-mediated activation of cAMP signaling, an effect that was pro-
portional to AhR agonism [109]. Whether EDCs similarly alter genes/
proteins regulating intermediary metabolism in adipocytes requires
further investigation.
5. Alterations in adipocyte endocrine function
In addition to storing and mobilizing energy, adipose tissue plays
an integral role in maintaining global energy homeostasis through
its function as an endocrine organ releasing a number of secreted
factors (adipokines) that regulate global insulin sensitivity, satiety,
energy expenditure, and inﬂammation [110]. Chief among these
adipokines are adiponectin and leptin, as well as additional secreted
factors such as resistin, TNFα, and interleukin-6 (IL-6). Dysregulation
of these adipokines has been implicated in the development of obesi-
ty and diabetes [110,111]. Recently, studies have examined how EDCs
modulate synthesis and release of these key metabolic hormones
(Table 2).
Leptin is a hormone secreted by adipocytes in proportion to fat
mass that signals the status of peripheral energy stores to the arcuate
nucleus of the hypothalamus, prompting changes in energy expendi-
ture and satiety [112–114]. Deﬁciencies in leptin secretion or signal-
ing promote the development of metabolic dysfunction, and leptin
resistance appears to develop in obesity [115]. While the extent towhich leptin resistance drives fat accretion remains controversial
[116], disruption of this metabolic circuit is an attractive molecular
target for studies of obesogenic EDCs. Several EDCs have been
shown to alter leptin levels in animal models, including BPA [117],
benzo[a]pyrene [108], and chlorpyrifos [86]. Prenatal exposure of
female mice to low doses of PFOA resulted in signiﬁcantly elevated
leptin levels in adulthood, an effect not observed in animals exposed
to high doses [118]. Because leptin is secreted in proportion to fat
mass, increased levels of this adipokine may merely reﬂect increased
adiposity rather than the causative mechanism for the increase in
adipose mass. However, exposure of Long–Evans rats to the organo-
phosphate insecticide chlorpyrifos resulted in an increase in body
weight coupled with an alteration in the relationship between body
weight and leptin levels, suggesting that impaired leptin release
and/or signaling may have contributed to the weight gain in this
model system [86]. In 3T3-L1 preadipocytes, incorporation of BPA
into the differentiation cocktail augmented leptin gene expres-
sion [119]; however, whether this reﬂects a change in the physiolog-
ical state of the adipocyte or is merely a marker of adipocyte
differentiation remains unclear. In primary murine fat, exposure to
TF has been shown to attenuate insulin-stimulated leptin release,
suggesting that disruption of adipocyte function by this EDC could
affect systemic energy homeostasis [102].
Adiponectin is an adipokine that acts both locally and globally as an
anti-inﬂammatory, anti-apoptotic, and insulin-sensitizing hormone
[reviewed in ref. [120]]. Thus, EDCs with the capacity to reduce
adiponectin release from adipose tissue and/or attenuate adiponectin
signal transduction have the capacity to adversely impact local and sys-
temic energy homeostasis. When incorporated into a low-potency in-
duction cocktail, BPA, DCHP, endrin, and TF all increased adiponectin
expression in 3T3-L1 adipocytes [32]; however, this ﬁnding likely re-
ﬂects increased adipogenesis rather than a physiological shift in the
functional state of those adipocytes. In contrast, PCB-77 augmented
3T3-L1 adipogenesis but reduced adiponectin gene expression and
basal release [37]. Likewise, TBT exposure reduced plasma adiponectin
levels in male KM mice despite an increase in body weight [35]. In
human tissue, environmentally-relevant BPA treatment of primary
breast, subcutaneous, and omental adipose tissue reduced basal
adiponectin release, suggesting onemechanismbywhichBPA can inﬂu-
ence systemic physiology [121].
Other adipocyte-secreted proteins also modulate local and sys-
temic energy metabolism. Resistin is an adipokine that correlates
with insulin resistance and has been found to be elevated in obese
and diabetic subjects [122], while IL-6, TNFα, and monocyte
chemoattractant protein-1 (MCP-1) are secreted factors that stimu-
late the immune response in adipose tissue [123]. These and other in-
ﬂammatory mediators provide an important link between obesity
and the development of diabetes [124]. Because EDCs are synthetic
compounds, it is likely that some activate cell stress pathways,
which may trigger the release of inﬂammatory mediators. Treatment
of 3T3-L1 adipocytes with octylphenol augmented resistin expression
and release in an estrogen receptor α- (ERα) and ERK-dependent
manner [125]. Similarly, chronic TBT exposure in male KM mice
elevated plasma resistin levels [35]. In parallel with the decrease in
adiponectin release, BPA exposure increased release of IL-6 and
TNFα from primary human adipose tissue [126]. When 3T3-L1
adipocytes were differentiated in the presence of PCB-77, they
exhibited augmented expression of the proinﬂammatory cytokines
angiotensinogen, TNFα, and CD36 [37]. Exposure of preadipocytes
and mature adipocytes to the AhR ligands TCDD and PCB-126
increased expression of the proinﬂammatory genes plasminogen acti-
vator inhibitor-1, MCP-1, and interleukin-8 [124]. Because inﬁltration
by inﬂammatory cells appears to play an important role in the induc-
tion of adipose insulin resistance, it is important that the increased
MCP-1 gene expression in male C57BL/6 mice exposed to TCDD was
accompanied by enhanced macrophage inﬁltration of fat [124].
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cascades are triggered and whether these effects can be predicted
for other EDCs.
6. Disruptions in metabolic cross-talk
Energy homeostasis is maintained through a network of coordi-
nated metabolic tissues, and adipose tissue dysfunction can adversely
affect energy homeostasis in other tissues. For example, impaired
lipid storage in adipose can result in increased lipid accumulation
and cellular disruption in liver and muscle [reviewed in refs. [82,127]].
EDCs that facilitate lipolysis such as PBDEs [100] or that antagonize
adipocytic insulin action like TF [102] and some POPs [96] could pro-
mote fatty acid efﬂux leading tometabolic dysfunction in liver andmus-
cle. In fact, several EDCs appear to induce hepatic steatosis, a state
arising from increased delivery of free fatty acids from adipose; impli-
cated compounds include TBT [35,128], BPA [129], TCDD [130], and
other POPs [reviewed in ref. [131]]. Because adiponectin improves ener-
gy utilization in muscle [132,133], sensitizes hepatocytes to insulin ac-
tion [134], and exerts multiple beneﬁcial effects on β-cell physiology
[135,136], compounds that speciﬁcally modulate adipokine secretion
could therefore exert multiple indirect effects on metabolism. Given
the central role of adipose tissue in energy homeostasis, EDCs that in-
duce changes in the global metabolic state of the organism should be
examined for initiating defects in adipose tissue.
Conversely, primary disruption of other metabolic tissues by EDCs
can result in adipose dysfunction. Because insulin deﬁciency can re-
sult in disturbances in adipose metabolism, compounds that alter
pancreatic β-cell physiology are of particular interest. Several EDCs
have been shown to modulate β-cell function or induce β-cell failure.
For example, the banned rodenticide pyrinuron (Vacor) is directly
toxic to β-cells and results in type 1 diabetes in those accidently or in-
tentionally exposed [137]. More recently, extensive work has shown
that BPA modulates β-cell function [107,138]. Additionally, heavy
metals like arsenic [139], cadmium [140], and others are known to
impair β-cell function [reviewed in ref. [141]]. Whether these com-
pounds induce the predicted indirect effects on adipocyte physiology
requires further exploration.
The liver also represents an important site of EDC-metabolism
cross-talk by virtue of its dual role in energy metabolism and detoxi-
ﬁcation. Whether EDC detoxiﬁcation generates chemical metabolites
with effects on hepatic energy metabolism that are distinct from the
parent compound is particularly important since the liver will likely
be enriched in these compounds. Such a paradigm of differential ef-
fects has been shown in adipose tissue where the compound DEHP
[56] and its primary metabolite MEHP [68] exert unique effects. Sim-
ilarly, generation of reactive oxygen species (or other by-products)
brought about by an up-regulation of detoxiﬁcation pathways to
eliminate EDCs from the body may also have spillover effects on
hepatic energy metabolism. Because the liver delivers growth factors
and nutrients back to adipose tissue, understanding how EDC-mediated
disruption of hepatic function impacts adipose function must be
explored.
7. Modeling metabolism: intrinsic complexities of
experimental systems
Diverse experimental models have been used to study the effects
of EDCs on metabolism (Tables 1 and 2). It is critical to recognize
that the model system employed may inﬂuence the phenotype ob-
served. For example, the CD-1 strain of mice appears to be resistant
to augmented body weight induced by BPA exposure [142]. As
discussed above, the divergent effects of DEHP versus its metabolite
MEHP on body weight may reﬂect differences in the metabolic effects
of those compounds; however, these divergent responses may also
reﬂect differential susceptibility of the C57BL/6J and C3H/N strains[40,41]. Interestingly, the protection against diet-induced obesity
conferred by exposure to DEHP in C57BL/6J was abolished in PPARα
humanized mice. These observations underscore the possibility of
model-dependent effects on metabolic perturbations elicited by EDC
exposure as well as potential differences between those models and
effects on human physiology.
In addition to potential differences in susceptibility to EDCs among
animal models, there is also differential sensitivity across the lifespan.
Supported by an increasing body of experimental evidence, the De-
velopmental Origins of Health and Disease (DOHaD) hypothesis
posits that many chronic diseases have their origins during develop-
ment, including insulin resistance and obesity [143,144]. Because
adipogenesis is particularly active during sensitive developmental
windows (i.e. in utero, postnatal, and peripubertal [145]), adipose tis-
sue may be particularly susceptible to EDCs during these periods. The
effects of EDCs on developmental programming have recently re-
ceived a great deal of attention [reviewed in refs. [146,147]]. For ex-
ample, female Sprague–Dawley rats exposed to BPA perinatally
(during gestation and lactation) exhibited augmented body weight
in adulthood [44]; neonatal exposure of male Long Evans rats to
BPA also resulted in increased adult body weight [148]. The impor-
tance of developmental exposure studies is highlighted by resultant
phenotypes not observed following equivalent adult exposures. For
instance, in utero exposure of CD-1 mice to PFOA resulted in increased
adiposity and hyperleptinemia, while adult exposure did not elicit
such effects [118]. Similarly, C57BL/6 mice exposed to lead in utero,
but not postnatally, showed increased body weight [43]. Notably,
the metabolic effects of developmental exposure may not manifest
until late adulthood. In male rats perinatally exposed to PCB-126, an
increase in body weight was not evident until 6 months of age [46],
while the increased body weight in mice following in utero lead expo-
sure was not evident until 12 months of age [43]. In contrast to these
studies, some compounds may exert effects only during adulthood.
For example, chronic exposure of adult female rats to the organo-
phosphate insecticide chlorpyrifos led to increased body weight
while perinatal exposure to female offspring had no effect on body
weight [47]. This suggests that sensitivity is a complex function of
both timing of exposure and the precise nature of that exposure.
The mechanisms by which EDCs exert persistent effects following
developmental exposure remain incompletely understood; however,
emerging evidence suggests that some of these effects are mediated
by changes in the epigenome [reviewed in ref. [149]]. These mecha-
nisms may have broader implications for metabolic health as some
epigenetic changes induced by EDC exposure may be passed
transgenerationally. Recently, the offspring of female C57BL/6J ex-
posed to TBT during pregnancy were shown to have expanded
adipose depots, enhanced adipogenic potential of MSCs, and aug-
mented lipid accumulation in the liver [128]. This phenotype contin-
ued through the F3 generation that had never been directly exposed
to the EDC. Importantly, multiple genes regulating adipocyte devel-
opment are regulated epigenetically via differential methylation pat-
terns of CpG islands within gene promoter regions, including BMP4
[150], FABP4 and PPARγ2 [151]. Additionally, the C/EBP family of
transcription factors bind to response elements that are highly meth-
ylated [59], suggesting one mechanism by which EDCs that modify
the epigenome might promote or inhibit adipocyte development.
Further studies are required to more completely elucidate the mech-
anisms, epigenetic or otherwise, underlying the metabolic perturba-
tions elicited by developmental EDC exposure.
8. The dose may not always make the poison: the challenge
of non-monotonicity
The dictum of toxicology that “the dose makes poison” has recently
been challenged by evidence that many EDCs exhibit non-monotonic
dose–response relationships in which biological effects are not directly
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in utero to PFOA exhibited increased body weight and adiposity during
adulthood with low dose exposure while higher doses did not alter
bodyweight or composition [118]. Male Long–Evans offspring perinatally
exposed to chlorpyrifos exhibited an inverted U-shaped dose–response
relationship with respect to weight gain [86]. Similarly complex
concentration-dependent effects are observed with in utero exposure to
DES or DDT in both male and female CF-1 mice. Low dose DES exposure
resulted in increased body weight in the postnatal period, while high
dose exposure resulted in reduced body weight; in contrast, high dose
exposure to DDT in utero led to elevated body weight, whereas lower
dose exposure reduced body weight [153]. Likewise, TCDD has been
shown to induce wasting at higher doses of exposure [154], while lower
doses result in weight gain [155]. Whether these divergent effects result
from alterations in the responsiveness of the same signal transduction
cascade or represent activation/inhibition of different pathways at differ-
ent concentrations requires further investigation.
As with the concentration-dependent effects, the duration of EDC
exposure may also be critical for determining the ultimate metabolic
phenotype. For example, TF up-regulated IRS-1 expression in adipo-
cytes after acute exposure [75], while more prolonged exposure
resulted in a reduction in IRS-1 levels and an attenuation in insulin
action [102]. Thus, differences in the duration of exposure may lead
to divergent metabolic phenotypes; this is particularly relevant if an
EDC has a relatively short in vivo half-life or if exposure is short
and/or episodic. Collectively, these ﬁndings underscore the impor-
tance of assessing biological effects across a wide range of concentra-
tions, with speciﬁc emphasis on environmentally relevant exposures
when the extent of those exposures is known. To date, many studies
of EDCs have been conducted at concentrations that may not reﬂect
relevant human exposure. While studies at pharmacological doses
can provide important insights into the mechanistic action of EDCs,
the complexities associated with non-monotonic dose–response
relationships may result in true metabolic effects that are either
over- or understated at levels of human exposure.
9. The challenges of coordinate stressors and mixtures
In addition to the challenges of dose, duration, and timing of exposure
to EDCs aswell as nuances of the experimental system, studyingmetabol-
ic disruption is also complicated by potential interactions. Because
humans are exposed to a plethora of chemicals, the effects of mixtures
on the ultimate phenotype have received increasing attention [88]. This
issue is immensely challenging as the list of chemicals to which humans
are exposed continues to grow and is now somewhere near 100,000 dis-
tinct compounds. Importantly, each individual is likely to be exposed to a
unique chemical cocktail, and the consequences of exposure to any specif-
ic combination may be dictated by antagonistic, additive, or synergistic
actions among those compounds. For example, a study examining puber-
ty inmale rats demonstrated that exposure to TBT resulted in signiﬁcantly
increased weight gain; however, concurrent exposure to the DDTmetab-
olite dichlorodiphenyldichloroethylene (DDE) abolished these effects
[156]. HowDDEantagonizes TBT-inducedweight gain is not clear, but un-
derscores the importance of characterizing the mechanisms by which
these compounds work in order to better predict how EDC interactions
might alter the ultimate metabolic phenotype of the exposed individual.
The complexities arising in even binary systems underscore the magni-
tude of the scientiﬁc challenge of predicting metabolic effects arising
from the seemingly inﬁnite combinations of potential exposures to
which any given individual might be subject. Reductionist methodologies
will remain critical for identifying and characterizingmolecular targets of
EDCs; however, alternative approaches are needed to fully demonstrate
the true threat to human health. Such efforts must include the identiﬁca-
tion of common EDC mixtures that have broad relevance to human pop-
ulations while incorporating the use of high throughput technologies to
study the metabolic consequences of those common EDC cocktails.Expanding our scientiﬁc approaches is fundamentally important for
achieving a better understanding of the vast complexities introduced by
mixtures.
In addition to the challenge of multiple exposures, the metabolic
consequences of a particular chemical mixture may also be inﬂuenced
by diet [157]. The connection between dietary fat and chemical expo-
sure was ﬁrst shown in 1974 when male rats exposed to the plasticiz-
er DEHP only exhibited augmented body weight gain and adiposity
when fat was present in the diet [158]. Interestingly, exposure of
mice to TCDD, most often associated with anorexigenic and wasting
effects [154], results in signiﬁcantly increased body weight if the an-
imals are also fed a high-fat diet [155]. Because of the clear role that
the “Western” diet plays in the obesity epidemic, understanding
how EDCs interact with caloric excess to promote metabolic disrup-
tion is critical for characterizing potential synergy among the various
factors that comprise an obesogenic environment. Furthermore, stud-
ies examining the mechanisms by which EDCs interact with speciﬁc
macronutrients in the diet, especially carbohydrates and fat, may sug-
gest potential molecular pathways disrupted by these compounds.
10. Potential beneﬁts of expanding fat mass
Lipid storage in adipose tissue protects against the accumulation
of ectopic lipid in other metabolic tissues that can adversely impact
global energy metabolism [82,127]. As discussed, EDCs that impair
expansion of adipose tissue mass may also be metabolically deleteri-
ous, as in clinical states of lipodystrophy. Interestingly, even excess
adiposity is not always deleterious. For example, overexpression of
adiponectin in ob/ob mice promotes greater weight gain but im-
proved metabolism [159]. Thus, it appears that the appropriate ex-
pansion of fat mass is critical for maintaining normal energy
homeostasis. Importantly, the deposition of triglycerides in adipose
tissue is likely accompanied by a similar enrichment of other lipophil-
ic compounds, including EDCs. While this bioaccumulation may ad-
versely affect adipose physiology, fat may also serve as an EDC sink
that protects against the deleterious effects of these compounds. In
a study examining the effects of the organophosphates diazinon and
parathion on neurodevelopment, the adverse effects were ameliorat-
ed by consumption of a high fat diet, suggesting that sequestration in
fat may play a protective role in limiting EDC toxicity [48]. Similarly,
adverse metabolic effects of PCB-77 were not seen in obese mice
but were induced upon weight loss [160], and diet-induced obesity
in female Long–Evans rats signiﬁcantly increased survival time fol-
lowing exposure to a lethal dose of TCDD [154]. Coupled with studies
showing that weight loss promotes the systemic release of EDCs from
adipose stores [161–164], these ﬁndings suggest that efforts at weight
loss may elicit adverse effects of EDCs brought about by their mobili-
zation from adipose stores. Whether mobilization of obesogenic EDCs
contributes to the difﬁculty that many patients have losing weight is
an interesting question that necessitates further study.
11. The future of adipose disruption: the need for more
mechanistic studies
Understanding the impact of environmental contaminants in the
etiology of obesity and its attendant metabolic disorders requires a
greater appreciation for the molecular mechanisms by which pollut-
ants modulate adipose physiology and global energy metabolism.
This is critical given the nearly 100,000 chemicals to which humans
are exposed since knowledge of mechanisms offers the best chance
at improving predictive models to identify chemicals that threaten
metabolic health. Advances in our understanding of adipocyte
physiology will help identify new targets that may be subject to endo-
crine disruption, thus providing insights into potential modes of in-
teractions among EDCs and between EDCs and other metabolic
stressors. Conversely, examination of EDC effects on adipocyte
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toxin targets (e.g. aryl hydrocarbon receptor, cytochrome P450 en-
zymes, etc.) in adipocyte energy homeostasis. Of critical interest to
the ﬁeld is the identiﬁcation of common mechanisms that integrate
signals from diverse classes of EDCs to alter adipose development
and function. Identiﬁcation of such common effectors will not only
provide insights into the pathways by which EDCs alter metabolism
but may also identify pharmaceutical targets to mitigate the deleteri-
ous impact of EDCs on metabolic homeostasis.
The failure of genetic studies to fully account for the predisposi-
tion to obesity has led some to propose that susceptibility to lifestyle
factors likely reﬂects the cumulative effects of small risks, perhaps
across multiple metabolic pathways [116]. Similarly, the contribution
of EDCs to the pathogenesis of metabolic diseases may be small for an
individual chemical working on a single signaling pathway; however,
when summated over thousands of chemicals operating through dis-
tinct pathways, the effects may be sufﬁcient to facilitate the develop-
ment of metabolic disease. Chemical exposures may also synergize
with the added insults of non-chemical disruptors of energy metabo-
lism (e.g. caloric excess, physical inactivity). Furthermore, underlying
genetics may augment an individual's susceptibility to particular
obesogenic or diabetogenic chemicals. Signiﬁcantly, that underlying
susceptibility may itself be inﬂuenced by developmental chemical ex-
posures through modiﬁcations of the epigenome, an emerging area in
the ﬁeld of EDC research [reviewed in refs. [146,147]]. Understanding
these complex interactions for an individual is therefore complicated;
however, a more thorough understanding of environmental contam-
inants and their mechanisms of action will greatly advance our
knowledge about this emerging risk factor, and may ultimately justify
regulatory action to prevent the deleterious impact of environmental
contaminants on human health.
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